Safety and effectiveness of ruxolitinib in real-world patients with myelofibrosis: A 2-year observational study from Taiwan.

Kuo, Ming-ChungMing-ChungKuoCHIEN-CHIN LINLin, Hsuan-YuHsuan-YuLinGau, Jyh-PyngJyh-PyngGauWang, Ming-ChungMing-ChungWangChang, Ming-ChihMing-ChihChangChen, Tsung-ChihTsung-ChihChenYeh, Shih-PengShih-PengYehChen, Yeu-ChinYeu-ChinChenHuang, Cih-EnCih-EnHuangChiang, I-JuI-JuChiangCheng, Hao-WeiHao-WeiChengLee, Yee-MingYee-MingLeeKu, Fan-ChenFan-ChenKuChang, Cheng-ShyongCheng-ShyongChang2024-12-192024-12-192024-1201452126https://scholars.lib.ntu.edu.tw/handle/123456789/724142Article number 107601enfalseMyelofibrosisPneumoniaReal-worldRuxolitinibTaiwan[SDGs]SDG3Safety and effectiveness of ruxolitinib in real-world patients with myelofibrosis: A 2-year observational study from Taiwan.letter10.1016/j.leukres.2024.107601394881952-s2.0-85207967706